SCHEMBL5153048

SCHEMBL5153048

Nc1cc2c3c(cc(N)cc3c1)C(=O)N(c1cc(C(=O)O)ccc1Cl)C2=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
TDP1 Q9NUW8 2/20 0.45
HPGD P15428 1/20 0.45
CA12 O43570 2/20 0.45
CA9 Q16790 2/20 0.45
CA1 P00915 1/20 0.45
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 1/20 0.42
CLTC Q00610 1/20 0.41
TSHR P16473 2/20 0.41
POLB P06746 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
CASP6 P55212 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
BRD1 O95696 1/20 0.39
TAF1 P21675 1/20 0.39
BRPF1 P55201 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5167514 0.93 CYP2C9 (0.56) CYP2C9CYP2C19TDP1HPGDCA12
SCHEMBL5163766 0.92 CYP2C9 (0.57) CYP2C9CYP2C19TDP1HPGDCA12
SCHEMBL14510363 0.85 CYP2C9 (0.63) CYP2C9CYP2C19TDP1HPGDCA12
SCHEMBL14502327 0.82 TDP1 (0.56) CYP2C9CYP2C19TDP1HPGDCA12
SCHEMBL5160000 0.81 MEN1 (0.65) CYP2C9CYP2C19TDP1HPGDCA12
SCHEMBL5167496 0.81 TDP1 (0.49) CYP2C9CYP2C19TDP1HPGDCA12
SCHEMBL5166807 0.80 CYP2C9 (0.44) CYP2C9CYP2C19TDP1HPGDCA12
SCHEMBL5162785 0.77 CYP2C9 (0.57) CYP2C9CYP2C19TDP1HPGDCA12
SCHEMBL5158766 0.76 KMT2A (0.66) TDP1HPGDCA12CA9ALDH1A1
SCHEMBL5159082 0.76 KMT2A (0.61) CYP2C9CYP2C19TDP1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US claimed
WO-2007030939-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO claimed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
WO-2007030939-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO disclosed
WO-2007030939-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 CYP2C9 4879/4885CYP2C19 4871/4885TDP1 2055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.